^
    Back
    Association details:
    Biomarker:MSI-H + HER-2 amplification
    Cancer:Colorectal Cancer
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2021
    Title:

    Relationship of HER2 alteration and MSI status in colorectal adenocarcinoma.

    Published date:
    01/11/2021
    Excerpt:
    MSI-H patients with HER2 mutation had significantly worse mPFS for PD-1 antibody than those without HER2 alteration, P = 0.036.